Unlike traditional cell-lines-based xenografts, which have a very poor ability to accurately predict clinical success, Champions TumorGrafts™ have been shown to accurately correlate with specific patient outcomes.
- Our patient derived xenograft (TumorGraft) models maintain a very high degree of genetic correlation (94%) to the original tumor.
- Champions TumorGrafts™ are established from the actual tumor sample, and not from a cell line that has been passaged in vitro, so:
- Our models have a 3-dimensional, heterogeneous structure that is more representative of the human cancer and maintains the cancer stem cells and stromal components.
- Because our xenograft model is derived from a single patient, Champions TumorGraftsTM can be molecularly characterized for targeted drug development in a manner in which traditional cell-line-based xenografts cannot.